Cargando…

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer

Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Po-Huang, Jhou, Hong-Jie, Chung, Chi-Hsiang, Wu, Yi-Ying, Huang, Tzu-Chuan, Lee, Cho-Hao, Chien, Wu-Chien, Chen, Jia-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864689/
https://www.ncbi.nlm.nih.gov/pubmed/36676634
http://dx.doi.org/10.3390/medicina59010010
_version_ 1784875645777477632
author Chen, Po-Huang
Jhou, Hong-Jie
Chung, Chi-Hsiang
Wu, Yi-Ying
Huang, Tzu-Chuan
Lee, Cho-Hao
Chien, Wu-Chien
Chen, Jia-Hong
author_facet Chen, Po-Huang
Jhou, Hong-Jie
Chung, Chi-Hsiang
Wu, Yi-Ying
Huang, Tzu-Chuan
Lee, Cho-Hao
Chien, Wu-Chien
Chen, Jia-Hong
author_sort Chen, Po-Huang
collection PubMed
description Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in patients with resected stage II colon cancer comparing the outcomes after postoperative adjuvant chemotherapy with UFT with an observation-only group. The data were collected from the Taiwan National Health Insurance Research Database from 2000 to 2015. The outcomes of the study were disease-free survival (DFS) and overall survival (OS). The hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression models. Results: No differences in the DFS and OS were detected between the UFT (1137 patients) and observation (2779 patients) cohorts (DFS: adjusted HR 0.702; 95% confidence interval (CI) 0.489–1.024; p = 0.074) (OS: adjusted HR 0.894; 95% CI 0.542–1.186; p = 0.477). In the subgroup analyses of the different substages, UFT prolonged DFS in patients with stage IIA colon cancer (adjusted HR 0.652; 95% CI 0.352–0.951; p = 0.001) compared with DFS in the observation cohort, but no differences in the OS were detected (adjusted HR 0.734; 95% CI 0.475–1.093; p = 0.503). Conclusions: Our results show that DFS improved significantly in patients with stage IIA colon cancer receiving UFT as a postoperative adjuvant chemotherapy compared with DFS in the observation group.
format Online
Article
Text
id pubmed-9864689
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98646892023-01-22 Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer Chen, Po-Huang Jhou, Hong-Jie Chung, Chi-Hsiang Wu, Yi-Ying Huang, Tzu-Chuan Lee, Cho-Hao Chien, Wu-Chien Chen, Jia-Hong Medicina (Kaunas) Article Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in patients with resected stage II colon cancer comparing the outcomes after postoperative adjuvant chemotherapy with UFT with an observation-only group. The data were collected from the Taiwan National Health Insurance Research Database from 2000 to 2015. The outcomes of the study were disease-free survival (DFS) and overall survival (OS). The hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression models. Results: No differences in the DFS and OS were detected between the UFT (1137 patients) and observation (2779 patients) cohorts (DFS: adjusted HR 0.702; 95% confidence interval (CI) 0.489–1.024; p = 0.074) (OS: adjusted HR 0.894; 95% CI 0.542–1.186; p = 0.477). In the subgroup analyses of the different substages, UFT prolonged DFS in patients with stage IIA colon cancer (adjusted HR 0.652; 95% CI 0.352–0.951; p = 0.001) compared with DFS in the observation cohort, but no differences in the OS were detected (adjusted HR 0.734; 95% CI 0.475–1.093; p = 0.503). Conclusions: Our results show that DFS improved significantly in patients with stage IIA colon cancer receiving UFT as a postoperative adjuvant chemotherapy compared with DFS in the observation group. MDPI 2022-12-20 /pmc/articles/PMC9864689/ /pubmed/36676634 http://dx.doi.org/10.3390/medicina59010010 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Po-Huang
Jhou, Hong-Jie
Chung, Chi-Hsiang
Wu, Yi-Ying
Huang, Tzu-Chuan
Lee, Cho-Hao
Chien, Wu-Chien
Chen, Jia-Hong
Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
title Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
title_full Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
title_fullStr Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
title_full_unstemmed Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
title_short Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
title_sort benefit of uracil–tegafur used as a postoperative adjuvant chemotherapy for stage iia colon cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864689/
https://www.ncbi.nlm.nih.gov/pubmed/36676634
http://dx.doi.org/10.3390/medicina59010010
work_keys_str_mv AT chenpohuang benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT jhouhongjie benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT chungchihsiang benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT wuyiying benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT huangtzuchuan benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT leechohao benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT chienwuchien benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer
AT chenjiahong benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer